Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
191 hedge funds and large institutions have $3.06B invested in Sage Therapeutics in 2017 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 61 increasing their positions, 73 reducing their positions, and 23 closing their positions.
18% more call options, than puts
Call options by funds: $163M | Put options by funds: $138M
14% more capital invested
Capital invested by funds: $2.69B → $3.06B (+$364M)
13% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 23
1.32% more ownership
Funds ownership: 101.61% → 102.94% (+1.3%)
1% more funds holding
Funds holding: 190 → 191 (+1)
16% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 73
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$115M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.9M |
| 3 |
Barclays
London,
United Kingdom
|
+$13M |
| 4 |
BlackRock
New York
|
+$12.2M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$7.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$24.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.5M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$11.4M |
| 4 |
DM
Deerfield Management
New York
|
-$8.67M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$8.52M |
SAGE Hedge Fund Activity: Q2 2017 in Review
191 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2017, worth a combined $3.06B — up 14% from $2.69B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new SAGE positions and 23 closed out — a net gain of 3 holders — while 61 added to existing stakes and 73 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $115M. The largest seller was Lord, Abbett & Co, cutting an estimated $24.1M.
- 191 institutional investors held Sage Therapeutics (SAGE) as of Q2 2017, up from 190 in Q1 2017.
- Funds reported $3.06B of Sage Therapeutics stock for Q2 2017, up 14% quarter-over-quarter.
- 26 funds opened new Sage Therapeutics positions in Q2 2017 and 23 closed out, a net change of +3 holders.
- The largest Sage Therapeutics buyer in Q2 2017 was Wellington Management Group, an estimated $115M added.
- The largest Sage Therapeutics seller in Q2 2017 was Lord, Abbett & Co, an estimated $24.1M sold.
Based on aggregated 13F filings for Q2 2017.